RxDoctor Payments Data

Afriyie Gray, DO

Geriatric Medicine · Grand Rapids, MINPI 1477842904

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (42.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Lilly USA, LLC accounts for 61.2% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $9,170 and has fallen 71.6% since, to $2,601 in 2025. Among geriatric medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,893in general payments, 2019–2025

Across 272 payments — averaging $43.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$7K
  • Amgen$1K
  • Novo Nordisk$785
  • AstraZeneca$599
  • GSK$420
  • Axsome Therapeutics, Inc.$280
  • plus $1K from 11 others

What the payments were for

  • Consulting fees$5,07543%
  • Travel & lodging$1,83215%
  • Food & beverage$4,98642%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,893 in reported general payments places this provider in the 95th percentile of 168 geriatric medicine providers in Michigan.

See all geriatric medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$22,790
Medicare patients
46
Services billed
296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban36$34,818
OzempicSemaglutide14$14,310
XareltoRivaroxaban11$13,854
EntrestoSacubitril/Valsartan18$13,238
MyrbetriqMirabegron15$10,444
Potassium Chloride55$3,561
Atorvastatin Calcium159$2,517
Levothyroxine Sodium178$2,110
Venlafaxine Hcl ErVenlafaxine Hcl17$2,069
Celecoxib17$1,958
Rosuvastatin Calcium92$1,917
Tamsulosin Hcl68$1,523
Ezetimibe58$1,507
Metoprolol Succinate81$1,477
Escitalopram Oxalate67$1,477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$785$14,31014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 168 geriatric medicine providers in Michigan.

Other geriatric medicine in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →